The FDA has accepted a biologics license application for a Huntington’s disease gene therapy for review, signaling another regulatory milestone for gene therapy in a difficult-to-treat neurological disease. The weekly update also notes new FDA potency guidance for cell and gene therapy manufacturers and MHRA approval of a Casgevy extension for younger patients. For professionals, these developments matter because potency expectations can affect manufacturing and review, while the label extension broadens access to an approved cell therapy.
Senator Bernie Sanders, a longtime critic of the pharmaceutical industry, is positioned to play a significant role in shaping the legislation that funds the FDA. The report says he could use that influence during drafting to press for reforms. Because FDA funding measures often carry substantive policy changes, his involvement matters for drugmakers, regulators, and others tracking the agency's direction.
Regulation & ApprovalCell Therapy IndustryRead more →
Rose BioSolutions CEO David Enloe argues that developers of advanced therapies should rethink how they work with contract development and manufacturing organizations, moving beyond a transactional outsourcing model. He contends that complex biologics and cell and gene therapies require earlier joint problem-solving, deeper scientific collaboration, and shared accountability between sponsors and manufacturers. The commentary matters for biotech leaders choosing manufacturing partners, since misaligned incentives and late-stage handoffs can translate into costly delays and quality risk.
Regulation & ApprovalCell Therapy IndustryRead more →
Advocates for a single-payer health system received a notable political opening this election, with Sen. Bernie Sanders likely to lead the Senate health committee next year. That role could give him a platform to fundamentally reshape how the FDA interacts with the companies it regulates. For professional readers, the shift signals a potentially more confrontational federal health oversight agenda and new pressure on industry relationships.
Researchers report that an AI-guided engineering approach produced a broadly protective avian influenza vaccine intended to remain effective across a wide range of current and future H5Nx variants. In preclinical testing, it outperformed vaccines currently held in stockpiles, suggesting a potential path to more durable preparedness against evolving bird flu threats.
Researchers at the National University of Singapore’s Yong Loo Lin School of Medicine have identified DUSP4 as a protein that may enhance CAR-T cell therapy. The finding is notable because CAR-T approaches have had limited success against solid tumors, so a potential booster could broaden their therapeutic reach. It remains early-stage research, but the result points to a new avenue for improving immune-cell treatment in solid cancers.
Researchers at UC San Francisco have engineered brain-sensing synNotch CAR T cells that remain dormant until they reach the brain, where they switch on and attack tumor cells. In mice, these cells cleared diffuse midline glioma, a deadly pediatric brain cancer. The approach could enable more tumor-localized cell therapy for hard-to-treat brain tumors, though the findings remain preclinical.
This week’s cell-therapy update includes an AI collaboration aimed at identifying biomarkers that may predict CAR-T response and toxicity, which could support safer and better-targeted treatment. A CRISPR-based system also differentiated human induced pluripotent stem cells toward pancreatic beta cells in four days, while a $550 million acquisition expanded Alcon’s retinal-disease offering. These developments reflect momentum in predictive tools, rapid cell differentiation, and commercial investment across the field.
Regenerative MedicineRegulation & ApprovalRead more →
Scientists have identified a protein, Mitch, whose inactivation makes human cells burn more fat and blocks the formation of new fat cells. The finding builds on mouse studies in which disabling the same target produced resistance to obesity and better muscular endurance. It points to a potential therapeutic target for obesity, though further work is needed to determine whether the effect translates into safe, effective treatments.